Dolutegravir or lower-dose efavirenz equally effective, but less resistance with dolutegravir

Dolutegravir-based treatment was no more effective than treatment based on a 400mg dose of efavirenz, a randomised trial conducted in Cameroon has found. However, almost half of people with very high viral loads taking either regimen had a detectable viral load after 48 weeks, the HIV Glasgow 2018 conference heard. Despite the non-inferiority of efavirenz-based… Read More »

Pricey Precision Medicine Often Financially Toxic For Cancer Patients

Kristen Kilmer hugs her 12-year-old daughter at their home in Spearfish, S.D.(Kristina Barker for KHN) When Kristen Kilmer was diagnosed with incurable breast cancer at age 38, her first thought was of her 8-year-old daughter. Kilmer lost her own mother as a teenager and was determined to get more time with her only child. Kilmer… Read More »